Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
about
Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditisTreatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesisLysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patientsTeicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureusBactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.Teicoplanin in the treatment of gram-positive-bacterial endocarditis.Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment.Methicillin-resistant staphylococci: detection methods and treatment of infections.Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus.Antibiotic penetration of and bactericidal activity within endothelial cells.Methicillin-resistant staphylococci.Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.Methicillin-resistant Staphylococcus aureus--an overview.Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis.Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditisEfficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infectionEffect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureusPoor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis.Comparison of the effectiveness of various antibiotics in the treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis.Vancomycin for treatment of infections with methicillin-resistant Staphylococcus aureus: are there alternatives?
P2860
Q24645282-364B949D-F10B-48AF-B36D-3619B4B173E1Q28368185-21AFC48C-0E3D-44D3-8723-69F6D903F8B9Q28379547-767EEDD9-31D2-44C9-BE96-C6AC6E44CDACQ33742289-642CEFCB-B6B3-4323-AD98-915E716115B5Q33756241-AE1893A9-B9BD-49D5-85F6-B42463A95B55Q33758399-2D11F601-EB75-4D61-B6E9-DC0F6DBD5DD9Q34885043-271894D2-692D-441E-8957-8E9354055DFBQ35344121-9CAE9C44-C48C-4A85-B2C7-9C6279C77C70Q35542699-8C4AC68B-9615-45BA-976F-4B39BFC83A1FQ35566190-3B2E67F2-FD6F-4C48-9FA8-603D1E9A3C20Q35648347-92A2A267-E230-4284-8942-576137974720Q35820407-4BBAF23D-7653-4A20-8107-20DB8D998493Q35820549-B9807A0C-98E9-4889-9FA7-5A264B4F6AE1Q36632851-0FC212BD-3249-4555-9346-0072967C4BA0Q36667020-F90E3862-143B-4BAB-85C5-6B3DD2C7F9A1Q36911203-91D3A9DA-B24F-4F9C-8C49-339422146D41Q37625071-CF6C019C-D95C-4B7D-9859-BFA45E251DC7Q39172014-026CA8C6-FBCA-488D-AA1D-6294C4F7EFEDQ39780630-EFB566E9-9FB1-4235-A95E-4B2EA9DE55EFQ39815914-7364D958-4367-404A-9AAE-96959E17148EQ39816915-BD559716-F743-48B7-8A03-FDA89A7708A3Q39832162-50E2AEF1-01A1-47EC-A01E-3E3E4CB6AD40Q41282587-419CEA72-D89B-4F64-B203-BED289A315EDQ43594419-D38D9E14-BABB-43E3-A344-119A30C5267AQ44055508-B2B3D095-83EC-402A-B992-CE5CAC000F60Q54418668-6D855194-20BA-4DEE-BAB3-0447BBC2E257
P2860
Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Teicoplanin versus nafcillin a ...... sistant Staphylococcus aureus.
@en
Teicoplanin versus nafcillin a ...... sistant Staphylococcus aureus.
@nl
type
label
Teicoplanin versus nafcillin a ...... sistant Staphylococcus aureus.
@en
Teicoplanin versus nafcillin a ...... sistant Staphylococcus aureus.
@nl
prefLabel
Teicoplanin versus nafcillin a ...... sistant Staphylococcus aureus.
@en
Teicoplanin versus nafcillin a ...... sistant Staphylococcus aureus.
@nl
P2860
P356
P1476
Teicoplanin versus nafcillin a ...... sistant Staphylococcus aureus.
@en
P2093
P2860
P356
10.1128/AAC.26.1.61
P407
P577
1984-07-01T00:00:00Z